Key Drivers
- Strong FCF
- Low leverage
- High SG&A drag
AIAI Summary
Progyny is shifting from a pure top‑line growth story to a cash‑generative, execution‑dependent business where durable free cash flow and buybacks provide a fundamental floor but near‑term returns hinge on utilization normalization and successful payback from recent investments. Monitor utilization trends, client transition metrics, and ROIC on incremental CapEx/hiring over the next 2–4 quarters—if those stabilize, margins and multiple should re-rate higher; if not, expect multiple compression despite strong cash flow.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •Low leverage
- •High SG&A drag
Pregnancy Co. generates strong free cash flow, low leverage, and high ROIC, but weak net margins, elevated SG&A and large investing outflows compress profitability and warrant monitoring.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near support
- •Large gap down
Over the last month the stock is in a clear short-term downtrend (≈ −13.6% from $20.98 to $18.13), sitting near support and carrying elevated downside risk after a large one-day gap down from $22.25 to $17.69 on 2026-02-27.
One-day gap down from $22.25 to $17.69 on 2026-02-27 indicating discrete-event risk
Sentiment & News
Key News Insights:
- •Strong cash flow
- •Buyback activity
- •Valuation support
Progyny is showing resilience—beat Q4 earnings, strong operating cash flow and sizable buybacks point to a medium‑term recovery despite muted FY26 growth and some analyst caution.
The quarter and capital returns should provide upward pressure on the stock's medium‑term outlook, though near‑term upside may be capped by cautious 2026 growth expectations
Similar Companies in Healthcare
Other companies in the same sector with AI ratings